Patent intelligence · US
US 12351644
Anti-CD73 antibodies
Anti-CD73 antibodies
Patent details — US 12351644
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 8, 2025
- Expiration
- Jul 3, 2045
- Applicant
- Corvus Pharmaceuticals, Inc.
- Claims
- 11
- CPC classes
- A61K, A61K2039/505, A61P, A61P35/00
Quick answer
US 12351644 (Anti-CD73 antibodies) is held by Corvus Pharmaceuticals, Inc.. Status: granted. Granted Jul 8, 2025. Expires Jul 3, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Corvus Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61K, A61K2039/505, A61P, A61P35/00
More from Corvus Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12174192
Methods for detecting and treating cancers having adenosine pathway activation
granted -
US 12116635
Methods for detecting and treating cancers having adenosine pathway activation
granted -
US 12023337
Methods of treating cancer
granted -
US 11897874
Compounds and methods for modulating Interleukin-2-inducible T-cell kinase
granted -
US 11859007
Humanized anti-CD73 antibodies
granted -
US 11266649
Pharmaceutical formulations
granted -
US 11254686
Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor
granted
Frequently asked questions
What is US patent 12351644?
US 12351644 (Anti-CD73 antibodies) is held by Corvus Pharmaceuticals, Inc.. Status: granted. Granted Jul 8, 2025. Expires Jul 3, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12351644?
Corvus Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 14 pharmaceutical patents for this assignee.
When does US 12351644 expire?
Our index shows an expiration date of Jul 3, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.